Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid
DOI:
https://doi.org/10.3855/jidc.559Keywords:
autoimmune thrombocytopenia, side effects, PEG-IFN-alpha, chronic hepatitis C, ursodeoxycholic acidAbstract
Pegylated interferon (PEG-IFN) alpha and ribavirin therapy has become the standard treatment in chronic hepatitis C virus (HCH)-infected patients. While thrombocytopenia associated with IFN use is frequently observed among these patients, autoimmune thrombocytopenia is one of the rarely observed adverse effects. In the present report, we present a case with chronic HCV infection in which autoimmune thrombocytopenia developed at week 7 of PEG-IFN alpha 2b plus ribavirin therapy. The patient subsequently received ursodeoxycholic acid (UDCA) treatment. Although there is not an adequate number of studies on this subject, it was concluded that the use of UDCA in cases of autoimmune thrombocytopenia that have developed due to PEG-IFN treatment in chronic HCV infection is a favorable option.
Downloads
Published
2009-09-15
How to Cite
1.
Naz H, Aslan V (2009) Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. J Infect Dev Ctries 3:644–646. doi: 10.3855/jidc.559
Issue
Section
Case Reports
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
